Etrasimod clinical trials
Also written APD334 and Velsipity.
How each study uses etrasimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the etrasimod studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 12 Oct 2023 · VELSIPITY · NDA 216956 (FDA, Drugs@FDA)
- European Union
- 16 Feb 2024 · Velsipity · EMEA/H/C/006007 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2020 (5)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 20 · Other 3
Pfizer (11) · Arena Pharmaceuticals (8) · Everstar Therapeutics Limited (1) · Sir Run Run Shaw Hospital (1) · Maia Kayal (1) · Yale University (1)
Related medicines
As reviewed, each with the page that says it.
- One of Immunomodulating Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test etrasimod.
- Jun 2027Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UCPhase 4 · Sir Run Run Shaw Hospital
Studies
Open first, then newest update. How each study uses etrasimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 23
- A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative ColitisRecruitingPhase 2PfizerNCT05287126Written as Etrasimod
- A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative ColitisRecruitingPhase 2PfizerNCT07470879Written as Etrasimod
- Etrasimod as Prevention of PouchitisRecruitingPhase 2Maia KayalNCT07486921Written as etrasimod
- Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UCNot yet recruitingPhase 4Sir Run Run Shaw HospitalNCT07782242Written as Etrasimod
- An Extension Study for Treatment of Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 3PfizerNCT03950232Written as Etrasimod
- A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding WomenCompletedPhase 1PfizerNCT07153159Written as Etrasimod
- A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's DiseaseTerminatedPhase 2/3PfizerNCT04173273Written as Etrasimod
- Etrasimod for Immune Checkpoint Inhibitor Diarrhea and ColitisWithdrawnPhase 2Yale UniversityNCT06521762Written as Etrasimod
- Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative ColitisCompletedPhase 2PfizerNCT04607837Written as Etrasimod
- A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by InjectionTerminatedPhase 2/3PfizerNCT05732454Written as etrasimod
- Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative ColitisCompletedPhase 2PfizerNCT05061446Written as Etrasimod
- Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia AreataCompletedPhase 2PfizerNCT04556734Written as Etrasimod
- A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic EsophagitisCompletedPhase 2PfizerNCT04682639Written as Etrasimod
- A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 3Everstar Therapeutics LimitedNCT04176588Written as Etrasimod
- Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)CompletedPhase 3PfizerNCT04706793Written as Etrasimod
- Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative ColitisCompletedPhase 3Arena PharmaceuticalsNCT03996369Written as Etrasimod
- Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative ColitisCompletedPhase 3Arena PharmaceuticalsNCT03945188Written as Etrasimod
- A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic DermatitisCompletedPhase 2Arena PharmaceuticalsNCT04162769Written as Etrasimod 1 mg
- Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary CholangitisTerminatedPhase 2Arena PharmaceuticalsNCT03155932Written as APD334
- Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative ColitisCompletedPhase 2Arena PharmaceuticalsNCT02536404Written as Etrasimod
Codes
What other systems call etrasimod · ClinicalTrials.gg INT001238
- MeSH (NLM) C000656249etrasimodConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 6WH8495MMHETRASIMODConfirmed FDA, NLM, Wikidata
- Wikidata Q27265630etrasimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166965EtrasimodOne source FDA
- DrugBank DB14766One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000656249 | etrasimod | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 6WH8495MMH | ETRASIMOD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27265630 | etrasimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166965 | Etrasimod | One source FDA |
| DrugBank | DB14766 | — | One source Wikidata |
Also registered as etrasimod arginine (UNII MXE5EMA09L).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.